Premium
S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension
Author(s) -
Tzouvelekis Argyrios,
HerazoMaya Jose D.,
Ryu Changwan,
Chu JenHwa,
Zhang Yingze,
Gibson Kevin F.,
AdontengBoateng Percy K.,
Li Qin,
Pan Hongyi,
Cherry Benjamin,
Ahmad Ferhaan,
Ford Hubert J.,
Herzog Erica L.,
Kaminski Naftali,
Fares Wassim H.
Publication year - 2018
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.13302
Subject(s) - medicine , biomarker , pulmonary hypertension , cohort , gastroenterology , idiopathic pulmonary fibrosis , cardiology , lung , peripheral , biochemistry , chemistry
Background and objective Molecular biomarkers are needed to refine prognostication and phenotyping of pulmonary hypertension (PH) patients. S100A12 is an emerging biomarker of various inflammatory diseases. This study aims to determine the prognostic value of S100A12 in PH. Methods Exploratory microarray analysis performed on peripheral blood mononuclear cells (PBMC) collected from idiopathic pulmonary fibrosis (IPF) patients suggested an association between S100A12 and both PH and mortality. So the current study was designed to evaluate for an association between S100A12 in peripheral blood collected from two well‐phenotyped PH cohorts in two other centres to derive and validate an association between S100A12 protein serum concentrations and mortality. Results The majority of the patients in the discovery and validation cohorts were either World Health Organization (WHO) group 1 (pulmonary arterial hypertension (PAH)) or 3 (lung disease‐associated) PH. In the discovery PH cohort, S100A12 was significantly increased in patients with PH ( n = 51) compared to controls ( n = 22) (29.8 vs 15.7 ng/mL, P < 0.001) and negatively correlated with cardiac output (r = −0.58, P < 0.001) in PH patients. When S100A12 data were pooled from both cohorts, PAH and non‐PAH PH patients had higher S100A12 compared to healthy external controls (32.6, 30.9, 15.7 ng/mL; P < 0.001). S100A12 was associated with an increased risk in overall mortality in PH patients in both the discovery ( n = 51; P = 0.008) and validation ( n = 40; P < 0.001) cohorts. Conclusion S100A12 levels are increased in PH patients and are associated with increased mortality.